Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Lexaria Bioscience Corp
(NQ:
LEXX
)
3.150
+0.010 (+0.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Lexaria Bioscience Corp
< Previous
1
2
3
4
5
Next >
Lexaria Bioscience Optimistic Of Positive Study Results
February 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice....
Via
Benzinga
Lexaria Optimistic About Expanded DehydraTECH Investigations
February 23, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria just announced ground-breaking...
Via
Benzinga
Lexaria World Leader Through DehydraTECH(TM) – Its Pioneering Drug Delivery Tech
February 22, 2022
Photo by Shelby Ireland on Unsplash
Via
Benzinga
Following Sildenafil Study, Lexaria Announces Plans For More Studies In 2022
February 17, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria’s animal study could be...
Via
Benzinga
Lexaria's DehydraTECH(TM) To Be Evaluated As Treatment For Multiple Conditions
February 14, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX)...
Via
Benzinga
Lexaria Technology Shows Promise In Improving Performance Of ED Drugs
February 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Health and wellness drug bio-...
Via
Benzinga
Lexaria Emphasizes Oral Cannabinoid Benefits Following SARS-CoV-2 Study
January 28, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Why Lexaria Shares Are Rising Today
December 08, 2021
Lexaria Bioscience Corp (NASDAQ:LEXX) is trading higher We...
Via
Benzinga
Lexaria CEO Summarizes 2021 Milestones in Letter to Shareholders
February 09, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. In 2021, Lexaria conducted several main studies evaluating...
Via
Benzinga
Lexaria Bioscience Announces Significant Findings From Sildenafil Animal Study
February 03, 2022
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has reported positive findings in its recent animal study.
Via
Benzinga
Lexaria CEO Offers A Glimpse Into Company's Unique Tech On EDGE Podcast
February 01, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Chris Bunka, the Chairman and CEO of Lexaria, featured on the...
Via
Benzinga
Lexaria Bioscience Marks Great Start to its 2022 R&D Programs
January 21, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria received independent review...
Via
Benzinga
Lexaria Bioscience Comments on Study Examining Cannabinoids and SARS-CoV-2
January 19, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience (NASDAQ: LEXX), a...
Via
Benzinga
Lexaria Bioscience Leveraging DehydraTECH(TM) for More Effective Oral Medicine
January 18, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience Corp. (NASDAQ: LEXX...
Via
Benzinga
Lexaria Bioscience Celebrates Productive Year for Blood Pressure Drug Solution
January 12, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria Bioscience’s ongoing...
Via
Benzinga
Lexaria Bioscience (NASDAQ: LEXX) Receives Independent Review Board Approval for Human Study
January 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Lexaria has received approval from the...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
January 07, 2022
Gainers ContraFect (NASDAQ:CFRX) stock mo...
Via
Benzinga
Lexaria Bioscience Increases Investor Visibility with SRAX
January 07, 2022
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. The strategic move to incorporate...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
January 06, 2022
Gainers ContraFect (NASDAQ:CFRX) stock in...
Via
Benzinga
Lexaria Bioscience Announces Approval from Independent Review for DehydraTECH-CBD Study
December 30, 2021
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has received Independent Review Board (“IRB”) approval for its planned DehydraTECH-...
Via
Benzinga
Lexaria Bioscience Expects Study Results to Show Patented Tech's Value in Treating Hypertension
December 28, 2021
Lexaria Bioscience is preparing to file an Investigational New Drug application with the U.S. Food and Drug Administration for its patented technology’s use in treating...
Via
Benzinga
Lexaria Bioscience Announces Major Discovery; Increasing Effectiveness of Orally Administered CBD
December 23, 2021
In a recent human clinical trial, HYPER-H21-2, DehydraTECH-CBD reduced arterial stiffness, potentially broadening Lexaria’s application’s ability to treat...
Via
Benzinga
Lexaria's DehydraTECH(TM) CBD Found to Reduce Arterial Stiffness in Study
December 17, 2021
Cardiovascular diseases are the leading cause of death worldwide and arterial stiffness serves as a significant marker of related conditions, including hypertension (high blood...
Via
Benzinga
Lexaria Bioscience Committed to Innovation and Improving Quality of Life
December 15, 2021
Lexaria presented at this year’s Benzinga Global Small Cap Conference held on December 8-9, 2021 The event came right after the company announced human clinical...
Via
Benzinga
Lexaria's Upcoming R&D Programs Targeting Global Markets Exceeding $160B
December 13, 2021
Lexaria Bioscience plans to launch approximately 12 applied research and development programs in 2022 The programs are designed to explore the ability of the company’s...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
December 10, 2021
Gainers Reshape Lifesciences (NASDAQ:RSLS...
Via
Benzinga
52 Biggest Movers From Yesterday
December 09, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares surged 84.1% to close at $19.11 on Wednesday. Insignia Systems recently announced the commencement of a formal process to...
Via
Benzinga
Lexaria Bioscience Featured in Virtual Coverage of Benzinga's Small Cap Conference
December 08, 2021
Lexaria Bioscience (NASDAQ: LEXX) is a global innovator in drug delivery platforms. The company leverages its patented technology, DehydraTECH(TM), to improve the delivery of...
Via
Benzinga
35 Stocks Moving In Wednesday's Mid-Day Session
December 08, 2021
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 79% to $18.63. Insignia Systems recently announced the commencement of a formal process to explore strategic options...
Via
Benzinga
Read Why Lexaria Bioscience Shares Are Surging During Wednesday Premarket?
December 08, 2021
Lexaria Bioscience Corp (NASDAQ: LEXX) has issued follow-up results from human clinical study HYPER-H21-2 of DehydraTECH-processed cannabidiol (CBD). The data...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.